(Q53446502)

14 May 2018

title

Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. (English)

1 reference

14 May 2018

1 reference

1 reference

1

1 reference

14 May 2018

author name string

S Lista

series ordinal

2

1 reference

14 May 2018

publication date

1 January 2013

1 reference

14 May 2018

The Journal of Nutrition, Health and Aging

published in

1 reference

14 May 2018

volume

17

1 reference

14 May 2018

page(s)

54-63

1 reference

14 May 2018

issue

1

1 reference

14 May 2018

https://scigraph.springernature.com/pub.10.1007/s12603-013-0003-1

exact match

0 references

cites work

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Reimagining Alzheimer's disease--an age-based hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Sting of Alzheimer's failures offset by upcoming prevention trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Prevention trials in Alzheimer's disease: an EU-US task force report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Biomarkers in Alzheimer's disease drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Pharmacodynamic biomarkers for molecular cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Diagnosis and biomarkers of predementia in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Evidence for ordering of Alzheimer disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Biomarkers for Alzheimer's disease therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Disease-modifying treatments for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Neurochemical aftermath of amateur boxing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Distinct destructive signal pathways of neuronal death in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Proteome-based plasma biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

A serum protein-based algorithm for the detection of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

A blood-based algorithm for the detection of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Preventing Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

US government sets out Alzheimer's plan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Drug Development Based on the Metals Hypothesis of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-013-0003-1

Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration

21 January 2018

1 reference

12 December 2020

Alzheimer's research. Stopping Alzheimer's before it starts

1 reference

12 December 2020

Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms

1 reference

12 December 2020

Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease

1 reference

12 December 2020

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

1 reference

12 December 2020

Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia

1 reference

12 December 2020

Drug development based on the metals hypothesis of Alzheimer's disease

1 reference

12 December 2020

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors

1 reference

12 December 2020

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease

1 reference

12 December 2020

Prevention of Alzheimer's disease: moving backward through the lifespan

1 reference

12 December 2020

Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal.

1 reference

12 December 2020

US scientists discuss early detection and treatment of Alzheimer's disease

1 reference

12 December 2020

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

1 reference

12 December 2020

10.1007/S12603-013-0003-1

Identifiers

DOI

1 reference

14 May 2018

PubMed ID

23299381

1 reference

14 May 2018